Acceleron Pharma, a biopharmaceutical company focused on the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept.
Imbrium Therapeutics, an operating subsidiary of Purdue Pharma, is advancing its novel, potentially first-in-class small molecule IMB-115 (previously referred to as IT-1315) to a Phase 2 clinical study following favorable results from Phase 1 studies evaluating the molecule’s safety and tolerability, including its potential for abuse and interaction with alcohol.
TILT Biotherapeutics has joined forces with Merck and Pfizer to evaluate the combination of its oncolytic adenovirus TILT-123 ((Ad5/3-E2F-D24-TNFa-IRES-IL2) with the duo’s avelumab for the treatment of solid tumours that are refractory to routine modalities.
NantKwest announced that the company’s PD-L1 t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers.
Horizon Therapeutics has announced the initiation of a clinical trial evaluating KRYSTEXXA (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD).
Ironwood Pharmaceuticals and Allergan said that their guanylate cyclase-C (GC-C) agonist LINZESS (linaclotide) 290mcg succeeded in a phase 3b trial on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C).
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease.
Boehringer Ingelheim and OSE Immunotherapeutics announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumours.
Alexion Pharmaceuticals announced the presentation of new data demonstrating that ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, provided consistent efficacy and safety through 52 weeks in the extension of the Phase 3 study of ULTOMIRIS and SOLIRIS (eculizumab) in complement inhibitor-naïve, adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.